Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Vitamin D Supplementation in Obesity and Weight Loss (3DD Study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01631292
Recruitment Status : Completed
First Posted : June 29, 2012
Last Update Posted : February 8, 2022
Information provided by (Responsible Party):
Sue A. Shapses, Ph.D., RD, Rutgers University

Brief Summary:
In this study, we will provide supplemental vitamin D in postmenopausal overweight/obese women, and hypothesize that it will not affect areal BMD, but will alter bone compartments (trabecular and cortical bone). In addition, higher vitamin D intake will increase serum 25OHD and suppress serum PTH and bone turnover during weight reduction. Secondary outcomes include the influence of vitamin D and weight loss on markers of insulin resistance and on cognitive tests of attention, learning, and memory.

Condition or disease Intervention/treatment Phase
Osteoporosis Dietary Supplement: 600 IU Vitamin D3 Dietary Supplement: 2000 IU Vitamin D3 Dietary Supplement: 4000 IU Vitamin D3 Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 81 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: A Pilot Dose Response Study to Vitamin D in Obesity and Weight Loss: Effect on Bone
Study Start Date : January 2010
Actual Primary Completion Date : May 2015
Actual Study Completion Date : December 30, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: 600 IU D3 Dietary Supplement: 600 IU Vitamin D3
Once daily

Active Comparator: 2000 IU D3 Dietary Supplement: 2000 IU Vitamin D3
Once daily

Active Comparator: 4000 IU D3 Dietary Supplement: 4000 IU Vitamin D3
Once daily

Primary Outcome Measures :
  1. Bone mineral density (BMD) [ Time Frame: 1 year ]

  2. Bone quality [ Time Frame: 1 year ]
    thickness (mm)

Secondary Outcome Measures :
  1. Bone turnover markers [ Time Frame: Baseline, 6mo, 12months ]
    osteocalcin (others include PINP and CTX)

  2. Glycemic indices [ Time Frame: Baseline, 6 mo and 12 months ]
    glucose and insulin

  3. Cognition and biochemical markers [ Time Frame: One year ]
    Cognitive measures and serum biochemical markers

  4. cholesterol absorption [ Time Frame: baseline and one year ]
    Serum levels

  5. serum vitamin D [ Time Frame: Baseline, 6 mo and 12 months ]

  6. Bone regulating hormones [ Time Frame: Baseline, 6 mo and 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 72 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Body mass index of 25-40 kg/m2,
  • Postmenopausal,
  • Age 50-72 years.

Exclusion Criteria:

  • Women who are taking any medication known to influence Ca or bone metabolism, or with evidence of diseases known to influence Ca metabolism (i.e. metabolic bone disease, hyperparathyroidism, untreated thyroid disease, significant immune, hepatic, or renal disease, a kidney stone in the last 5 yrs., significant cardiac disease, active malignancy or cancer therapy within the past year) are not eligible.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01631292

Layout table for location information
United States, New Jersey
Rutgers University- Thompson Hall
New Brunswick, New Jersey, United States, 08901
Sponsors and Collaborators
Rutgers University
Layout table for investigator information
Principal Investigator: Sue Shapses, PhD Rutgers University
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Sue A. Shapses, Ph.D., RD, Professor, Rutgers University Identifier: NCT01631292    
Other Study ID Numbers: BBGP201095157
First Posted: June 29, 2012    Key Record Dates
Last Update Posted: February 8, 2022
Last Verified: February 2022
Additional relevant MeSH terms:
Layout table for MeSH terms
Weight Loss
Body Weight
Body Weight Changes
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Vitamin D
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents